Dec 07, 2020
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
Nov 30, 2020
Achieve Life Sciences Announces Proposed Public Offering
Oct 27, 2020
Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020
Oct 07, 2020
Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Sep 30, 2020
Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President
Sep 18, 2020
Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study
Sep 18, 2020
Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study
Sep 03, 2020
Achieve Life Sciences to Present at Upcoming Investor Conferences
Aug 06, 2020
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
Aug 03, 2020
Achieve Life Sciences Announces Proposed Public Offering
Jul 31, 2020
Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
Jun 29, 2020
Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
Jun 29, 2020
Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking
May 14, 2020
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
Apr 30, 2020
Achieve Life Sciences Announces Private Placement of $1.9 Million
Mar 13, 2020
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
Mar 12, 2020
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
Jan 13, 2020
Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
Dec 19, 2019
Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
Dec 17, 2019
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering